From GlobeNewswire: 2025-05-19 20:01:00

Mainz Biomed N.V. (NASDAQ:MYNZ) announced the pricing of a follow-on offering of 2,000,000 units, with gross proceeds of approximately $4.0 million. Each unit consists of one ordinary share, one Series A warrant, and one Series B warrant, each sold at an effective price of $2.00 per unit. The offering is expected to close on May 21, 2025, with Maxim Group LLC as the sole placement agent. The Company also entered into a Warrant Amendment Agreement to reduce the strike price of previously issued warrants. The offering is made pursuant to a registration statement declared effective by the SEC on May 16, 2025.

Mainz Biomed develops molecular genetic diagnostic solutions, including ColoAlert® for colorectal cancer detection. The Company is currently conducting clinical studies for FDA approval. For more information, visit mainzbiomed.com. Forward-looking statements in the press release caution about risks and uncertainties, urging reliance on current information. Actual results may differ due to various factors, such as the failure to meet development targets, changes in laws, and the impact of the COVID-19 pandemic. Mainz Biomed commits to updating forward-looking statements as required by law.



Read more at GlobeNewswire: Mainz Biomed Announces Pricing of $4.0 Million Follow-On